Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EUNHS New Drugs Online Report for catridecacog Page accessed July 2, 2015, is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.Catridecacog: First drug to treat rare genetic blood clotting disorder . The Pharmacist February 01, 2014 It was brought to market by Novo.
References
External links